Loading candles…
Laurus Labs Ltd., incorporated in 2005, is a research-focused pharmaceutical and biotechnology company operating in the pharmaceuticals, biotechnology, human and animal health, crop science, and specialty ingredients industries. The company specializes in manufacturing Active Pharmaceutical Ingredients (APIs), including those for anti-retroviral, oncology (with high-potency APIs), cardiovascular, and gastro therapeutics. It also offers integrated Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) services ranging from clinical phase drug development to commercial production. Laurus Labs holds a global leadership position in select APIs and serves as a preferred partner for both innovator and generic pharmaceutical firms. It operates more than 11 manufacturing facilities approved by regulatory agencies such as USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, and TGA. The company employs over 6,500 individuals, including approximately 1,050 scientists.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 30 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 23 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and dividend | 23 Oct 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 25 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 24 Apr 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.